GET DAILY SIGNALSBlack Diamond Therapeutics (BDTX) Holds Near $1.75 After -4% Monthly Move
Key Takeaways
- Black Diamond Therapeutics is a clinical-stage precision oncology company focused on silevertinib, a brain-penetrant fourth-generation EGFR inhibitor targeting EGFR-mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM).
- BDTX traded near $1.75 in late October 2026, a decline of roughly 4% over the prior 30 days, keeping shares in a rangebound, low-price pattern.
- Phase 2 data presented at the 2026 ASCO Annual Meeting showed a 60% objective response rate, 86% CNS objective response rate, and preliminary median progression-free survival of 15.2 months in frontline EGFR non-classical mutation NSCLC.
- The company is seeking FDA feedback on a pivotal development path and expects to provide an update on both the pivotal path and its Phase 2 NSCLC program in the fourth quarter of 2026.
- Black Diamond ended the second quarter of 2026 with approximately $110.5 million in cash, cash equivalents, and investments, which the company expects to fund operations into the second half of 2028.
- Additional detail on valuation and expectations is available on the company's Price Targets, Earnings, and Forecast pages.
- Traders can also explore Trending AI Robots to see how AI-driven strategies approach this and other tickers.
Current Market Snapshot
Black Diamond Therapeutics (BDTX) has been trading in a low single-digit range as investors weigh clinical momentum against the inherent risks of a development-stage biotech. Over the 30-day window ending in late October 2026, the stock declined roughly 4%, closing near $1.75 after briefly trading above $2.00 earlier in the period. The modest move reflects a market that is largely waiting for the company's next major catalyst rather than repricing the stock sharply on new fundamental data.
The broader small-cap biotech sector has remained sensitive to interest-rate expectations and risk appetite, and BDTX, with no approved products or recurring revenue, is particularly exposed to shifts in sentiment. Within this context, the stock's relatively contained 30-day move contrasts with the more pronounced swings that often accompany clinical readouts for oncology names. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Business Overview and Competitive Position
Black Diamond Therapeutics is a clinical-stage oncology company developing "MasterKey" therapies designed to target families of oncogenic mutations in patients with cancer. Its lead program, silevertinib (formerly BDTX-1535), is an oral, covalent, brain-penetrant fourth-generation EGFR tyrosine kinase inhibitor that selectively targets classical and more than 50 non-classical EGFR mutations in NSCLC, as well as key EGFR alterations seen in glioblastoma, including EGFRvIII.
The company's positioning centers on addressing underserved patient populations. Patients with non-classical EGFR mutations have historically shown poor progression-free survival on available frontline tyrosine kinase inhibitors, and brain metastases remain a frequent source of disease progression. Silevertinib's demonstrated central nervous system activity, including an 86% CNS objective response rate and the absence of de novo brain metastases in its Phase 2 frontline NSCLC cohort, underpins the company's thesis of a differentiated, potentially best-in-class profile. In 2025, Black Diamond out-licensed its BDTX-4933 RAF/RAS program to Servier, concentrating resources on silevertinib. From what I see, this focus on a single asset sharpens the risk-reward profile.
Recent Developments Driving BDTX
The most significant recent development for Black Diamond has been the maturation of its silevertinib dataset. At the 2026 ASCO Annual Meeting, the company presented updated Phase 2 results in frontline NSCLC patients with a broad spectrum of EGFR non-classical mutations. Highlights included a 60% objective response rate, a 91% disease control rate, a preliminary median progression-free survival of 15.2 months, a median duration of response that had not yet been reached, and no patients developing de novo brain metastases. Management has cited safety and efficacy data supporting a 150 mg once-daily dose for pivotal development.
Operationally, the company reported second-quarter 2026 results showing research and development expenses of approximately $7.4 million and a cash position of about $110.5 million as of June 30, 2026. In parallel, Black Diamond has been advancing a randomized Phase 2 trial of silevertinib in combination with temozolomide in newly diagnosed EGFRvIII-positive glioblastoma, with the randomized portion of the study expected to begin in the fourth quarter of 2026. One thing that stands out here is the durability signals in the data.
2026 Outlook and What Investors Should Watch
The next several months are pivotal for Black Diamond Therapeutics. Investors are focused on the company's anticipated fourth-quarter 2026 update on the FDA's feedback regarding a pivotal development path for silevertinib in frontline non-classical EGFR-mutant NSCLC, as well as additional data from the ongoing Phase 2 program. Initiation of the randomized portion of the glioblastoma trial represents a second near-term milestone.
Beyond these catalysts, key factors to monitor include clinical durability data, the safety profile at the proposed pivotal dose, potential partnership or financing decisions, and the pace of cash consumption. As a pre-revenue company, Black Diamond's ability to fund operations into the second half of 2028 provides runway, but clinical and regulatory outcomes will ultimately determine the value of its pipeline. Macroeconomic conditions and risk appetite in the biotech sector may also continue to influence share-price volatility. I’m watching this closely as the regulatory update approaches.
Incorporating Tickeron AI Tools Into My Process
In my own research, I often turn to Tickeron’s AI Trading Bots to test how automated strategies have historically handled names like BDTX. These tools let me compare performance across different timeframes and risk parameters without building everything from scratch. It adds a useful quantitative layer to the fundamental picture I’ve outlined above.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BDTX's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for BDTX turned positive on October 20, 2026. Looking at past instances where BDTX's MACD turned positive, the stock continued to rise in 38 of 42 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BDTX's RSI Indicator exited the oversold zone, 28 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +14.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDTX advanced for three days, in 198 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 51 cases where BDTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
The Momentum Indicator moved below the 0 level on October 26, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BDTX as a result. In 57 of 70 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
BDTX moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BDTX crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
BDTX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BDTX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.046) is normal, around the industry mean (3.037). P/E Ratio (-2.333) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (2.360) is also within normal values, averaging (439.237).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. BDTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company that discovers and develops therapeutic agents to target unique oncogenic protein-isoforms.
Industry Biotechnology
Advertisement